Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex PCR workflows

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its innovative LILRB4/CD3 TCE bispecific antibody (R&D code: 6MW5311). The drug candidate is being developed for hematologic malignancies, specifically Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM).

Novo Nordisk today announced a strategic partnership with OpenAI that will place Novo Nordisk at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster. The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient. It has been structured with strict data protection, governance and human oversigh

Haisco Pharmaceutical Group Co., Ltd. announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds designed to address pain-related indications. These compounds are current

TriNetX, the world’s leading federated health data network, today announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX’s genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers’ ability to integrate phenotypic and multiomic data for improved care delivery and clinical re

Halozyme Therapeutics, Inc. today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon™ technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection vol

Merck known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock val

The Pharma Partnering Summit (PPS US) 2026 is set to return to San Diego, California, on April 29–30, 2026, uniting senior business development and licensing (BD&L) professionals from the pharmaceutical and biotechnology sectors. This premier partnering forum provides an unrivaled platform for deal-making, strategic collaborations, and investment opportunities. Over two high-impact days, executives, investors, and innovators will engage in pre-arranged one-on-one meetings,

The Pharma Partnering EU Summit 2026 will take place in Basel, Switzerland, on May 20–21, 2026, bringing together global leaders in business development and licensing from pharmaceutical and biotech organizations. The summit provides a dynamic, partnership-focused environment for executives, innovators, and investors to explore licensing deals, co-development opportunities, joint ventures, and strategic alliances. With Basel’s reputation as a European pharmaceutical hub,

Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis. Cryogenic electron microscopy (cryo-EM), an ad